Ratiometric co-delivery of hydroxychloroquine and calculated low-dose paclitaxel efficiently suppresses tumor growth in hepatocellular carcinoma mouse models in vivo
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Microtubule and mitosis dynamics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Hepatocellular Carcinoma10.1056/NEJMra1713263 ↗
2. Hepatectomy for huge hepatocellular carcinoma: single institute’s experience10.1007/s00268-013-2095-5 ↗
3. Hepatocellular carcinoma10.1038/nrdp.2016.18 ↗
4. International Agency for Research on Cancer, World Health Organization. Cancer today 〈http://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf〉.
5. Immune checkpoint inhibitors in the treatment of HCC
6. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): subgroup analyses from CheckMate 04010.1200/JCO.19.01535 ↗
7. A new treatment combination for liver cancer
8. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma10.1056/NEJMoa1712126 ↗
9. Manganese carbonate nanoparticles-mediated mitochondrial dysfunction for enhanced sonodynamic therapy10.1002/EXP.20210010 ↗
10. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model10.1111/cas.13806 ↗
11. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance10.1080/15548627.2019.1580105 ↗
12. Targeted and immune-based therapies for hepatocellular carcinoma10.1053/j.gastro.2018.09.051 ↗
13. U.S. Food & Drug Administration. 〈https://www.fda.gov〉.
14. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice10.1021/acsnano.5b00510 ↗
15. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment10.1038/s41467-020-17996-7 ↗
16. Efficient nano-enabled therapy for gastrointestinal cancer using silicasome delivery technology10.1007/s11426-021-1126-x ↗
17. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer10.1038/s41591-019-0368-8 ↗
18. Atg5 siRNA inhibits autophagy and enhances norcantharidin-induced apoptosis in hepatocellular carcinoma10.3892/ijo.2015.3103 ↗
19. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype10.1038/s41467-018-03225-9 ↗
20. Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models10.1016/j.isci.2020.101990 ↗
21. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I10.1038/s41586-020-2229-5 ↗
22. Paclitaxel and its formulations10.1016/S0378-5173(01)00986-3 ↗
23. An analysis of 412 cases of hepatocellular carcinoma at a Western center10.1097/00000658-199906000-00005 ↗
24. Mouse models for liver cancer10.1016/j.molonc.2013.01.005 ↗
25. Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination10.1016/j.jconrel.2016.01.020 ↗
26. Significantly enhanced tumor cellular and lysosomal hydroxychloroquine delivery by smart liposomes for optimal autophagy inhibition and improved antitumor efficiency with liposomal doxorubicin10.1080/15548627.2016.1162930 ↗
27. A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer10.1016/j.phrs.2019.01.013 ↗
28. Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis10.1158/2326-6066.CIR-19-0616 ↗
29. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy10.7150/thno.45391 ↗
30. Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-110.1002/advs.202002147 ↗
31. FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia10.1158/1078-0432.CCR-18-2990 ↗
32. Hepatocellular carcinoma: a global view10.1038/nrgastro.2010.100 ↗
33. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?10.1634/theoncologist.11-7-790 ↗
34. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
35. Nanoparticle-assisted combination therapies for effective cancer treatment10.4155/tde.10.13 ↗
36. Codelivery of doxorubicin and shAkt1 by poly(ethylenimine)-glycyrrhetinic acid nanoparticles to induce autophagy-mediated liver cancer combination therapy10.1021/acs.molpharmaceut.5b00879 ↗
37. Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy10.1186/s12951-017-0261-x ↗
38. Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways10.1016/j.jconrel.2018.08.015 ↗
39. Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor10.1016/j.biomaterials.2020.120635 ↗
40. Role of autophagy in cancer10.1038/nrc2254 ↗
41. The roles of autophagy in cancer10.3390/ijms19113466 ↗
42. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice10.1021/nn404083m ↗
43. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer10.1172/JCI92284 ↗
44. Triple bioluminescence imaging for in vivo monitoring of cellular processes10.1038/mtna.2013.25 ↗